Análisis de la acción Esperion Therapeutics Inc (ESPR)ESPREsperion Therapeutics Inc

Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and delivering cardiometabolic and rare/orphan disease therapies. It markets two oral, once-daily, non-statin therapies for patients struggling to maintain their low-density lipoprotein cholesterol (LDL-C) levels who are at risk of cardiovascular disease and nasal spray, loop diuretic for the treatment of edema associated with congestive heart failure, and hepatic and renal disease. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. NEXLETOL is a first-in-class ACLY inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating LDL receptors. NEXLIZET contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and cholesterol absorption in the intestine. Its Enbumyst is the FDA-approved nasal spray loop diuretic. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

ESPR is not a good buy right now for a Beginner long-term investor with $50,000-$100,000 to deploy. The stock is effectively priced at the acquisition level of $3.16, leaving very limited upside from the current $3.17 close. Since the investor is impatient and does not want to wait for a better entry, the best direct conclusion is to avoid buying new shares now and wait for a clearer catalyst or a better risk/reward setup. If already holding, this is more of a hold than an aggressive buy.

11 analysts cover ESPR: 9 rate it Buy, 2 Hold and 0 Sell. The average price target is 7.94.